For research use only. Not for therapeutic Use.
Adoprazine (SLV313) is a full 5-HT1A receptor agonist with a pEC50 of 9 at cloned h5-HT1A receptors. Adoprazine (SLV313) is a full D2 and D3 receptor antagonist with pA2s of 9.3 and 8.9 at hD2 and hD3 receptors, respectively. Adoprazine (SLV313) has the characteristics of atypical antipsychotics[1].
Adoprazine (SLV313) has high affinity at human recombinant D2, D3, D4, 5-HT2B, and 5-HT1A receptors, with pKis of 8.4, 8.4, 8.0, 7.9 and 9.1, respectively[1].
Adoprazine (SLV313) acts as a high potency dopamine D2 receptor antagonist and an efficacious serotonin 5-HT1A receptor agonist, with Emax value (% effect of 10 μM 5-HT) of 73 and pKB value of 8.5 [2].
Adoprazine (SLV313) (0.1-10 mg/kg; p.o.; single) is sufficient to reduce extracellular 5-HT and increase dopamine levels in the nucleus accumbens in a dose- and time-dependent manner[1].
| Catalog Number | I001228 |
| CAS Number | 222551-17-9 |
| Synonyms | 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazine |
| Molecular Formula | C24H24FN3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H24FN3O2/c25-21-6-4-19(5-7-21)20-14-18(15-26-16-20)17-27-8-10-28(11-9-27)22-2-1-3-23-24(22)30-13-12-29-23/h1-7,14-16H,8-13,17H2 |
| InChIKey | IUVSEUFHPNITEQ-UHFFFAOYSA-N |
| SMILES | C1CN(CCN1CC2=CC(=CN=C2)C3=CC=C(C=C3)F)C4=C5C(=CC=C4)OCCO5 |
| Reference | [1]. Andrew C McCreary, et al. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsych [2]. Liesbeth A Bruins Slot, et al. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol. 2006 Mar 18;534(1-3):63-70. |
